<DOC>
	<DOCNO>NCT00889733</DOCNO>
	<brief_summary>The purpose study determine whether intraperitoneal ( IP ) Cisplatin combine intravenous ( IV ) Paclitaxel well tolerate woman epithelial ovarian cancer neoadjuvant chemotherapy follow initial debulking surgery .</brief_summary>
	<brief_title>Intraperitoneal ( IP ) Cisplatin Given With Paclitaxel Treat Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven epithelial ovarian cancer Previously receive 4 cycle neoadjuvant platinum base chemotherapy , follow debulking surgery ECOG PFS &lt; _ 2 Adequate haematological ( absolute neutrophil count &gt; _ 1,500/mm3 ; platelet &gt; _ 100,000/mm3 ; hemoglobin &gt; _ 100g/L ) ; renal ( &lt; _ upper limit normal ) hepatic function Age &gt; _ 18 year Written inform consent ability patient cooperate treatment follow Contraindication platinum/Paclitaxel chemotherapy : prior anaphylaxis Carboplatin/Paclitaxel , unresolved excessive toxicity neoadjuvant chemotherapy . Patients must suffer significant bone marrow suppression prior treatment . The significance previous treatment delay and/or dose modification determine Principle Investigator patientbypatient basis . Serious concomitant medical condition , investigator opinion would make patient good candidate clinical trial . Patients past concomitant malignancy skin cancer ( exclude melanoma ) Patients know serologically positive Hepatitis B , C HIV History congestive heart failure unstable angina myocardial infarction within past 6 month . Patients expect tolerate hemodynamic effect fluid administer part IP protocol . Patients receive chemotherapy prior surgery Greater 6 week time surgery commencement IP chemotherapy Residual disease great 1 cm time surgery . Patients surgeon 's opinion candidate surgery may consent preoperatively allow intraoperative IP catheter insertion . If however surgeon able reduce bulk disease less equal 1 cm , patient remove study IP catheter SHOULD NOT place .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>